- 全部删除
- 您的购物车当前为空
BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water solubility, and high plasma protein binding.
BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water solubility, and high plasma protein binding.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 13,900 | 8-10周 | |
50 mg | ¥ 18,300 | 8-10周 | |
100 mg | ¥ 23,500 | 8-10周 |
产品描述 | BMS-695735, a benzimidazole inhibitor of insulin-like growth factor-1 receptor, has broad-spectrum antitumor activity in vivo. It was found that BMS-695735 had strong inhibition of CYP3A4, induction of CYP3A4 mediated by PXR transactivation, poor water solubility, and high plasma protein binding. |
别名 | DNC008930, CHEMBL459729, BMS695735, BMS 695735, BDBM27888 |
分子量 | 512.02 |
分子式 | C26H31ClFN7O |
CAS No. | 1054315-48-8 |
密度 | 1.41 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容